NQO1 is a determinant for cellular sensitivity to anti-tumor agent Napabucasin.
NQO1
NRF2
Napabucasin
ROS
proteomics
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
03
2020
accepted:
25
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Napabucasin (NAPA) is thought to be a potent cancer stemness inhibitor in different types of cancer cell lines. While it has shown promising activity in early phase clinical trials, two recent phase III NAPA clinical trials failed to meet the primary endpoint of overall survival. The reason for the failure is not clear, but a possible way to revive the clinical trial is to stratify patients with biomarkers that could predict NAPA response. Here, we report the identification of NAD(P)H dehydrogenase 1 (NQO1) as a major determinant of NAPA efficacy. A proteomic profiling of cancer cell lines revealed that NQO1 abundance is negatively correlated with IC
Types de publication
Journal Article
Langues
eng
Pagination
1442-1454Informations de copyright
AJCR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Drugs. 2017 Jul;77(10):1091-1103
pubmed: 28573435
Cancer Med. 2016 Jun;5(6):1251-8
pubmed: 26899963
Nature. 2019 Mar;567(7747):257-261
pubmed: 30814741
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Int J Oncol. 2008 Oct;33(4):833-8
pubmed: 18813798
Biochem Pharmacol. 2017 Dec 15;146:74-86
pubmed: 29066190
Oncogene. 2019 Jan;38(4):533-548
pubmed: 30158673
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44
pubmed: 25605917
In Vivo. 2019 May-Jun;33(3):933-937
pubmed: 31028219
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
J Exp Clin Cancer Res. 2018 Oct 4;37(1):244
pubmed: 30286779
Cell Prolif. 2020 Jan;53(1):e12719
pubmed: 31778258
Nat Biotechnol. 2017 May 9;35(5):409-412
pubmed: 28486446
J Nat Prod. 1982 Sep-Oct;45(5):600-4
pubmed: 7153777
Nat Rev Drug Discov. 2019 Apr;18(4):295-317
pubmed: 30610225
Med Sci Monit. 2019 Nov 24;25:8905-8912
pubmed: 31760402
J Nat Prod. 2018 Jul 27;81(7):1636-1644
pubmed: 30003778
Clin Cancer Res. 2004 May 1;10(9):3147-55
pubmed: 15131056
Sci Rep. 2015 Nov 25;5:17066
pubmed: 26602448
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
J Pineal Res. 2016 Sep;61(2):187-97
pubmed: 27117941
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nucleic Acids Res. 2019 Jan 8;47(D1):D1211-D1217
pubmed: 30252093
Biochem J. 2013 Nov 15;456(1):47-54
pubmed: 24015818
Nat Commun. 2018 Mar 8;9(1):1012
pubmed: 29520031
Biomedicines. 2018 Mar 16;6(1):
pubmed: 29547556
Nat Commun. 2019 Jan 3;10(1):39
pubmed: 30604760
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Colloids Surf B Biointerfaces. 2018 Mar 1;163:225-235
pubmed: 29304437
Mol Cancer Res. 2019 Jul;17(7):1429-1434
pubmed: 31043490
Acc Chem Res. 2015 Oct 20;48(10):2715-23
pubmed: 26444384
Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270
pubmed: 29397354
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Cancer Cell. 2016 Dec 12;30(6):940-952
pubmed: 27960087
J Neurochem. 2008 Feb;104(4):1116-31
pubmed: 17995931
Clin Cancer Res. 2019 Dec 1;25(23):7162-7174
pubmed: 31527169
R Soc Open Sci. 2018 Dec 5;5(12):181006
pubmed: 30662724
Future Oncol. 2018 Apr;14(10):901-906
pubmed: 29297698
Clin Cancer Res. 2011 Jan 15;17(2):275-85
pubmed: 21224367
Free Radic Biol Med. 2007 Jun 1;42(11):1690-703
pubmed: 17462537
Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707
pubmed: 28683005
Cancer Res. 2012 Jun 15;72(12):3038-47
pubmed: 22532167
EBioMedicine. 2019 Aug;46:119-132
pubmed: 31375423
Cancer Cell. 2019 Jan 14;35(1):111-124.e10
pubmed: 30645970
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054